Walmart Recall Update: Customers Told Not to Consume Products Nationwide
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Walmart has so far announced that four food products sold in its stores nationwide have been recalled in July.
The latest, on Monday, was Danone U.S.' voluntarily recall of all flavors and sizes of its YoCrunch yogurt, following consumer complaints about the potential presence of sharp, transparent plastic pieces in the yogurt's dome topper, the company said.
Why It Matters
This recall marks the latest in a series of notable product recalls issued so far this year.
Food recalls due to contamination or mislabeling can undermine consumer trust and place vulnerable individuals (such as children, the elderly, or those with allergies) at greater risk.
Food safety remains a paramount concern for American households, and the frequency of such issues may influence shopping habits and regulatory responses nationwide.
A Walmart Supercenter cart sits outside of the store on February 20, 2024, in Hallandale Beach, Florida.
A Walmart Supercenter cart sits outside of the store on February 20, 2024, in Hallandale Beach, Florida.Full List of Walmart Product Recalls in July 2025
July 2 — Oscar Mayer Turkey Bacon (Kraft Heinz)
Kraft Heinz pulled nearly 368,000 pounds of fully-cooked Oscar Mayer Turkey Bacon after in-house tests suggested possible Listeria monocytogenescontamination. The bacon—sold nationwide, including at Walmart—carries "use by" dates from July 18 to Sept 4 and lot codes RS19, RS40 or RS42. No illnesses have been reported, but shoppers are urged to throw out or return the product.
July 8 — RITZ Peanut Butter Cracker Sandwiches (Mondelēz)
Mondelēz voluntarily recalled select 8-, 20- and 40-count cartons of RITZ Peanut Butter Cracker Sandwiches—and a variety pack—because some individual packs were mis-wrapped in "Cheese" film, hiding the peanut allergen inside. The mislabeled snacks, sold nationwide at retailers such as Walmart, pose a serious risk to people with peanut allergies. No injuries have been reported.
July 10 — Lewis Bake Shop Artisan Style Half-Loaf (Hartford Bakery)
Hartford Bakery yanked six lots of its Lewis Bake Shop Artisan Style Half-Loaf bread after visible hazelnuts turned up in packaging that failed to disclose the tree-nut ingredient. About 883 loaves reached Walmart and other stores across 12 states. One minor digestive complaint has surfaced; customers can return the bread for a full refund.
July 14 — YoCrunch Yogurts (Danone U.S.)
Danone recalled all flavors and sizes of its YoCrunch yogurt line after consumers found clear plastic shards—7 to 25 mm long—in the dome toppers. The nationwide recall, affecting multipacks and single 6-oz cups sold at Walmart and other chains, was issued over choking concerns. Consumers should discard the yogurts or seek a refund through YoCrunch's helpline.
What People Are Saying
Walmart says in a statement on its product recall webpage: "Walmart and Sam's Club are committed to the health and safety of our customers and members and to providing products that are safe and compliant, all supported by our health and wellness, product safety, and food safety professionals. In the event of a product recall, we work swiftly to block the item from being sold and remove it from our stores and clubs."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
37 minutes ago
- UPI
Larger statin dosages urged for many with cholesterol, heart risks
1 of 2 | Dr. Charles Hennekens, a medical school professor and heart disease researcher at Florida Atlantic University in Boca Raton, Fla., says too many patients at high risk of heart attacks and stroke are being "underdosed" with beneficial statin drugs. Photo by Alex Dolce, Florida Atlantic University ST. PAUL, Minn., July 31 (UPI) -- Doctors are routinely "underdosing" statins for patients at risk for heart attacks and strokes due to elevated levels of "bad" cholesterol, even though the drugs have proven safe and effective, a top U.S. researcher maintains. At a time when an estimated 40% of U.S. adults have metabolic syndrome -- a combination of heart risk factors including obesity, hypertension, dyslipidemia and insulin resistance -- doctors usually don't start them off with the maximum dosage of statins, even though they can quickly lower levels of LDL cholesterol, according to an opinion published this month in the medical journal Trends in Cardiovascular Medicine. Co-author Dr. Charles Hennekens, the Sir Richard Doll Professor of Medicine and Preventive Medicine at Florida Atlantic University's Charles E. Schmidt College of Medicine in Boca Raton, says his analysis of several major clinical studies of the new generation of highly potent statins, such as rosuvastatin and atorvastatin, shows that maximal doses are safe and sorely needed, but aren't being prescribed. Those with metabolic syndrome have cardiovascular risks equivalent to those with prior heart attacks or strokes, yet many are "undertreated" by starting their statin regimens at low or moderate dosages, Hennekens told UPI. "The data indicate that over half of people who were put on a statin remain on the initial dose they're given, so even though the intent may be to titrate it up, it's not done in the majority of instances," he said. "So, you get on a low dose of statin and you stay on it." But this "flies at the face of the data" showing that statins "have the strongest and most consistent body of evidence supporting their prescription in treatment and prevention in both men and women including older adults," he said. "There's no threshold for LDL below which you don't see incremental benefits." The studies demonstrate newer statins can lower LDL, or bad cholesterol, in as quickly as a month and can provide related benefits, such as stabilizing the build-up of harmful plaque on the cells that line the interior surface of blood vessels, Hennekens said. Therefore, he urges cardiologists who initiate drug therapies for those with metabolic syndrome to start statins at maximal tolerated levels. "Everything points to getting on the highest dose of evidence-based statin," he noted. "The goal of LDL in the high-risk secondary patients is less than 50 [milligrams per deciliter], and we have a lot to do to achieve that goal because there are lots of forces in society, especially in American society, that are making that more difficult. "For example, in the United States today, in middle-age people gain 7 to 10 pounds of body weight every 10 years, so we have a society that's fatter, but only about 21% of Americans reach the daily minimum recommendation for daily physical activity, Hennekens said. "We have a nation that would benefit enormously from therapeutic lifestyle changes, but in the end, we have such high absolute risk that many are going to require adjunctive therapy." And if so, "we make a strong case that the first one you should consider is a statin, and that every other adjunctive therapy should be viewed in the context of residual risk after the statin is given with maximal doses," Hennekens added. Other experts on the use of statins to control LDL cholesterol contacted by UPI generally agreed with the premise that dosages should start at maximum levels for those at high risk of heart disease. Dr. Laurence Sperling, the Katz Professor in Preventive Cardiology at the Emory University School of Medicine in Atlanta, noted it's already on a list of guidelines developed in 2018 by an American College of Cardiology/American Heart Association joint task force. "In patients with clinical atherosclerotic cardiovascular disease, [the guidelines say] reduce LDL cholesterol with high-intensity statin therapy or maximally tolerated statin therapy," he said. "The more LDL cholesterol is reduced on statin therapy, the greater will be subsequent risk reduction." Sperling said he agreed with the recommendation to use "a maximally tolerated statin to lower LDL-C levels by 50%." Joseph Saseen, a researcher and professor of clinical pharmacy at the University of Colorado's Skaggs School of Pharmacy and Pharmaceutical Sciences in Boulder, told UPI one reason for the low-dosage prescriptions is that cardiologists overestimate the chances of possible side effects, such as muscle aches and digestive problems. "While dose-related side effects can occur, they do not justify the routine underdosing of statins in high-risk populations," Saseen said. "Clinicians too often initiate therapy at suboptimal doses, particularly in patients with elevated [cardiovascular] risk. Evidence-based guidelines recommend starting high-intensity statin therapy, especially very high-risk secondary prevention patients." Clinical data have shown, for instance, that initiating atorvastatin at as much as 80 mg. daily "is both safe and effective in reducing cardiovascular events among secondary prevention patients," Saseen said. "Similarly, rosuvastatin at 20 mg. has been shown to be a safe and effective starting dose in primary prevention patients with elevated [high-sensitivity C-reactive protein]." Also agreeing with Hennekens' conclusion is Dr. Paul Heidenreich, a practicing cardiologist, professor at the Stanford University School of Medicine and chief of medicine at the Palo Alto, Calif., Veterans Affairs clinic. "When high intensity statins are indicated, one can recommend starting with the high intensity or beginning with moderate intensity followed by up-titration," he said. He noted some cardiologists are concerned that if patients can't tolerate a high-intensity statin, they may subsequently refuse all statins, in which case it may be better to start off with a moderate dose. "However, I feel it is rare that the patient will refuse to try a lower dose," Heidenreich said. "As the authors note, titration to a higher intensity is not as frequent as it should be, with patients staying on the initial intensity. Thus, patients are likely better off starting with the recommended high-intensity statin." The clinical data also showed that the rate of intolerance with a placebo "was surprisingly high, suggesting that patients are on the lookout for any new symptom that occurs following initiation of a new medication. It is important to stress that the vast majority of patients tolerate statins medications without side effects," he said.
Axios
2 hours ago
- Axios
Trump brings back the Presidential Fitness Test in public schools
President Trump will revive the Presidential Fitness Test in public schools, which was phased out more than a decade ago, a White House official confirmed to Axios on Thursday. The big picture: The test — featuring challenges like a one-mile run, pull-ups and the sit-and-reach — was once a rite of passage for America's youth. It was also a source of anxiety and shame for more than a few kids, who ended up feeling like they weren't strong enough for the president's (or Arnold Schwarzenegger ' s) purposes. Trump on Thursday will sign an executive order to reestablish the President's Council on Sports, Fitness and Nutrition, which includes re-establishing the test, as first reported by CNN. Why it matters: The Trump administration has focused on sports and athletics, including banning transgender athletes and hosting major national and international sporting events. State of play: Then-President Dwight D. Eisenhower established the test in 1956 to assess cardiovascular fitness, upper body and core strength, endurance, flexibility and agility, according to Harvard Health. The test included a one-mile run, pull-ups or push-ups, sit-ups, shuttle run, and sit-and-reach. Children in the top 15% received the Presidential Physical Fitness Award, established by former President Lyndon B. Johnson. President Obama replaced the test after the 2012-13 school year and instituted the Presidential Youth Fitness Program, putting more emphasis on students' health rather than performance, per Education Week. Flashback: Eisenhower originally established the test out of panic over American children being less fit than European children, Vox reported. One of its early iterations was akin to a military training exercise. What's next: The Presidential Fitness test will be administered by Health and Human Services Secretary Robert F. Kennedy Jr. The executive order directs the council to create school programs rewarding excellence in physical education and develop criteria for a fitness award. What they're saying: "President Trump wants to ensure America's future generations are strong, healthy, and successful," White House press secretary Karoline Leavitt said in a statement.
New York Times
2 hours ago
- New York Times
New Implant Offers Hope for Easing Rheumatoid Arthritis
The Food and Drug Administration on Wednesday approved a medical device that offers new hope to patients incapacitated by rheumatoid arthritis, a chronic condition that afflicts 1.5 million Americans and is often resistant to treatment. The condition is usually managed with medications. The device represents a radical departure from standard care, tapping the power of the brain and nervous system to tamp down the uncontrolled inflammation that leads to the debilitating autoimmune disease. The SetPoint System is an inch-long device that is surgically implanted into the neck, where it sits in a pod wrapped around the vagus nerve, the largest nerve in the body. The device electrically stimulates the nerve, a sort of information freeway through the body, for one minute each day. The stimulation can turn off crippling inflammation and 'reset' the immune system, research has shown. Most drugs used to treat rheumatoid arthritis suppress the immune system, leaving patients vulnerable to serious infections. On a recent episode of the American College of Rheumatology podcast, the SetPoint implant was described as representing a 'true paradigm shift' in treatment of the disease, which until now has relied almost entirely on an evolving set of pharmaceutical interventions, from gold salts to powerful agents called biologics. The designated the implant as a breakthrough last year in order to expedite its development and approval. It represents an early test of the promise of so-called bioelectronic medicine to modulate inflammation, which plays a key role in diseases including diabetes, heart disease and cancer. Want all of The Times? Subscribe.
